Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.55 |
| ▸ | HTR2A | P28223 | 6/20 | 0.55 |
| ▸ | HTR2B | P41595 | 6/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14278464 | 0.84 | SLC5A2 (0.57) | SLC5A1SLC5A2LTA4H | |
| SCHEMBL3036049 | 0.78 | ABCB1 (0.52) | SLC5A2LTA4HMAPTEGFRPDGFRB | |
| SCHEMBL3091118 | 0.77 | GPR84 (0.65) | HTR2ALTA4HADRB2 | |
| SCHEMBL27542807 | 0.73 | HTR2C (0.67) | HTR2CHTR2AHTR2BMAPT | |
| SCHEMBL14278474 | 0.73 | KMT2A (0.46) | SLC5A1SLC5A2 | |
| SCHEMBL254705 | 0.73 | KEAP1 (0.63) | ALOX5SLC5A1SLC5A2LTA4H | |
| SCHEMBL26965705 | 0.71 | HTR2A (0.65) | HTR2CHTR2AHTR2B | |
| SCHEMBL14278469 | 0.71 | SLC5A2 (0.57) | SLC5A1SLC5A2 | |
| SCHEMBL2931184 | 0.71 | HTR2C (0.63) | HTR2CHTR2AHTR2BMAPT | |
| SCHEMBL26965630 | 0.71 | HTR2C (0.68) | HTR2CHTR2AHTR2BMAPTADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820630-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-26 | — | — | US | disclosed |
| US-20100009916-A1 | SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS | BOKVIST BENGT KRISTER | 2010-01-14 | — | — | US | disclosed |
| US-20100009900-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | BEAVERS MARY PAT | 2010-01-14 | — | — | US | disclosed |
| EP-1680131-A4 | SUBSTITUTED INDOLE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | disclosed |
| US-20090105164-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | BEAVERS MARY PAT | 2009-04-23 | — | — | US | disclosed |
| US-7511022-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
| US-20060293251-A1 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-28 | — | — | US | disclosed |
| US-7129220-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V (BE) | 2006-10-31 | — | — | US | disclosed |
| EP-1680131-A2 | SUBSTITUTED INDOLE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-19 | — | — | EP | disclosed |
| US-20050037981-A1 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
| WO-2005012243-A2 | SUBSTITUTED INDOLE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009900-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | GPR119, PYGL, IAPP | HTR2C 267/4885HTR2A 168/4885HTR2B 188/4885 |
| US-20090105164-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | GPR119, PYGL, IAPP | HTR2C 267/4885HTR2A 168/4885HTR2B 188/4885 |
| US-20050037981-A1 | Substituted indole-O-glucosides | GPR119, PYGL, IAPP | HTR2C 267/4885HTR2A 168/4885HTR2B 188/4885 |
| US-20060293251-A1 | Substituted indazole-O-glucosides | GPR119, PYGL, GYS2 | HTR2C 786/4885HTR2A 1089/4885HTR2B 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.